BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN

BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

1,619 Followers
See the Price Targets and Ratings of:

BMRN Analyst Ratings

Strong Buy
14Ratings
12 Buy
2 Hold
0 Sell
Based on 14 analysts giving stock ratings to
BioMarin
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BMRN Stock 12 Months Forecast

Average Price Target

$103.62
▲(2.61% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $103.62 with a high forecast of $133.00 and a low forecast of $23.00. The average price target represents a 2.61% change from the last price of $100.98.
Highest Price Target$133.00Average Price Target$103.62Lowest Price Target$23.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Credit Suisse
$110.00
Buy
8.93%
Upside
Reiterated
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $110 at Credit SuisseCredit Suisse analyst Tiago Fauth lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $110.00 (from $111.00) while maintaining a Outperform rating.
RBC Capital
$95.00
Hold
-5.92%
Downside
Reiterated
BioMarin Pharmaceutical (BMRN) Receives a Hold from RBC Capital
Stifel Nicolaus
$104.00
Buy
2.99%
Upside
Reiterated
Cantor Fitzgerald
$115.00
Buy
13.88%
Upside
Reiterated
BioMarin price target raised to $115 from $110 at Cantor FitzgeraldBioMarin price target raised to $115 from $110 at Cantor Fitzgerald
Barclays
$125.00
Buy
23.79%
Upside
Reiterated
Barclays Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $125
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

BMRN Financial Forecast

BMRN Earnings Forecast
Next quarter’s earnings estimate for BMRN is -$0.08 with a range of -$0.21 to $0.01. The previous quarter’s EPS was -$0.04. BMRN beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.54% of the time in the same period. In the last calendar year BMRN has Outperformed its overall industry.
Next quarter’s earnings estimate for BMRN is -$0.08 with a range of -$0.21 to $0.01. The previous quarter’s EPS was -$0.04. BMRN beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.54% of the time in the same period. In the last calendar year BMRN has Outperformed its overall industry.
BMRN Sales Forecast
Next quarter’s sales forecast for BMRN is $537.00M with a range of $507.40M to $589.30M. The previous quarter’s sales results were $490.06M. BMRN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.84% of the time in the same period. In the last calendar year BMRN has Outperformed its overall industry.
Next quarter’s sales forecast for BMRN is $537.00M with a range of $507.40M to $589.30M. The previous quarter’s sales results were $490.06M. BMRN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.84% of the time in the same period. In the last calendar year BMRN has Outperformed its overall industry.
BMRN Analyst Recommendation Trends
In the current month, BMRN has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BMRN average analyst price target in the past 3 months is $103.62
In the current month, BMRN has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BMRN average analyst price target in the past 3 months is $103.62

BMRN Stock Forecast FAQ

What is BMRN’s average 12-month price target, according to analysts?
Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is $103.62.
    What is BMRN’s upside potential, based on the analysts’ average price target?
    BioMarin Pharmaceutical has 2.61% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BMRN a Buy, Sell or Hold?
          BioMarin Pharmaceutical has a conensus rating of Strong Buy which is based on 12 buy ratings, 2 hold ratings and 0 sell ratings.
            What is BioMarin Pharmaceutical’s price target?
            The average price target for BioMarin Pharmaceutical is $103.62. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $133.00 ,the lowest forecast is $23.00. The average price target represents 2.61% Increase from the current price of $100.98.
              What do analysts say about BioMarin Pharmaceutical?
              BioMarin Pharmaceutical’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis